Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Food Order Intervention for Gestational Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03592784
Recruitment Status : Terminated (Lack of enrollment during Covid pandemic, however sufficient data gathered for assessment of primary outcome)
First Posted : July 19, 2018
Last Update Posted : November 23, 2020
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This is a randomized controlled feasibility trial for women diagnosed with gestational diabetes mellitus (GDM). The current front-line treatment for GDM is medical nutrition therapy (MNT), i.e. personalized diets which may or may not include mild carbohydrate restriction. Use of carbohydrate restriction increases the risk of the mother developing ketosis, a harmful condition for both the mother and fetus. If MNT is not enough to stabilize blood sugar levels, then pharmaceuticals are prescribed. In patients with type-2 diabetes and prediabetes, the carbohydrate-last food order behavior has been shown to improve post-meal blood sugar control without the need of reduced carbohydrate intake. Given this data, the addition of this intervention to MNT in patients with GDM may be helpful in achieving controlled blood sugar levels without increasing the risk of ketosis. This study will include two randomized groups diagnosed with GDM. Patients in the control group will be prescribed standard MNT. Patients in the intervention group will have identical MNT but with additional food order instruction/therapy. All patients will be followed up with at 1-2 week intervals. At each follow-up the physician and dietician will analyze the patient's blood sugar measurements and, among additional factors, determine if pharmaceuticals should be added. Treatment will continue through delivery. The primary aim of this study is to assess the feasibility of the carbohydrate last food order in GDM and generate preliminary data on its effects on glucose control.

Condition or disease Intervention/treatment Phase
Gestational Diabetes Behavioral: Food Order Therapy Behavioral: Medical Nutrition Therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Carbohydrate-Last Food Order Intervention for Gestational Diabetes Mellitus
Actual Study Start Date : June 18, 2018
Actual Primary Completion Date : March 19, 2020
Actual Study Completion Date : April 22, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Food Order Therapy + Medical Nutrition Therapy Behavioral: Food Order Therapy
Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.

Behavioral: Medical Nutrition Therapy
Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.

Active Comparator: Medical Nutrition Therapy Alone Behavioral: Medical Nutrition Therapy
Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.




Primary Outcome Measures :
  1. Feasibility of the Food Order Intervention [ Time Frame: 8 weeks ]
    Measured via feasibility questionnaire.


Secondary Outcome Measures :
  1. Average 1-hour postprandial glucose [ Time Frame: 2, 4, 6, 8, 10, 12 weeks ]
    Averaged from self-monitored blood glucose logs.

  2. Time to initiation of pharmacotherapy [ Time Frame: 2, 4, 6, 8, 10, 12 weeks ]
    Measured in weeks from enrollment in the study.

  3. Proportion of patients requiring the addition of pharmacotherapy [ Time Frame: Week 16 or End of study (at delivery) ]
    Measured as a percentage of patients in each arm.

  4. Birthweight [ Time Frame: Week 16 or End of study (delivery) ]
    Measured in lbs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pregnant subjects ≥18 years old
  • Newly diagnosed with GDM between 24-32 weeks of gestation with at least 2 days of self-monitored glucose logs or diagnosed via a 50g glucose challenge test (GCT) greater than 200mg/dL

Exclusion Criteria:

  • Pre-existing diabetes prior to conception
  • Patients whom do not plan on consuming at least 3 meals daily throughout gestation (e.g. during Ramadan)
  • Requirement of special medical diet (e.g. from phenylketonuria, celiac disease, etc.)
  • History of bariatric surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03592784


Locations
Layout table for location information
United States, New York
Materal-Fetal Medicine of Weill Cornell Medicine
New York, New York, United States, 10065
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Alpana P Shukla, MD Weill Medical College of Cornell University
Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03592784    
Other Study ID Numbers: 1802018956
First Posted: July 19, 2018    Key Record Dates
Last Update Posted: November 23, 2020
Last Verified: November 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes, Gestational
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications